GlaxoSmithKline的季节性MRNA流感疫苗符合第二阶段试验成功标准和进入第三阶段的进展。 GlaxoSmithKline's seasonal mRNA influenza vaccine met Phase 2 trial success criteria and advances to Phase 3.

GlaxoSmithKline(GSK)宣布,在对季节性MRNA流感疫苗进行第二阶段试验后,取得了有希望的成果,该试验有效地引起了对不同年龄组的甲型和乙型流感菌株的免疫反应。 GlaxoSmithKline (GSK) announced promising results from a Phase 2 trial of its seasonal mRNA influenza vaccine, which effectively elicited immune responses against both influenza A and B strains in various age groups. 疫苗符合所有预先确定的成功标准,将进入第3阶段临床发展阶段。 Meeting all predefined success criteria, the vaccine is set to advance to Phase 3 clinical development. 这项倡议符合全球疫苗方案在现有药品收入减少的情况下加强其疫苗组合的战略。 This initiative aligns with GSK's strategy to enhance its vaccine portfolio amid declining revenues from existing medications.